Developmental programming: Prenatal and postnatal androgen antagonist and insulin sensitizer interventions prevent advancement of puberty and improve LH surge dynamics in prenatal testosterone-treated sheep

Endocrinology

Volumn 156, Issue 7, 2015, Pages 2678-2692

  Padmanabhan, Vasantha ^a   Veiga Lopez, Almudena ^a,b   Herkimer, Carol ^a   Salloum, Bachir Abi ^a   Moeller, Jacob ^a   Beckett, Evan ^a   Sreedharan, Rohit ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; LUTEINIZING HORMONE; METFORMIN; PROSTAGLANDIN F2 ALPHA; ROSIGLITAZONE; TESTOSTERONE PROPIONATE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIANDROGEN; ANTIDIABETIC AGENT; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOGENITAL DISTANCE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; EWE; FEMALE; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; NONHUMAN; OVINE MODEL; PERINATAL PERIOD; PRECOCIOUS PUBERTY; PRENATAL PERIOD; PRIORITY JOURNAL; PROGENY; ANIMAL; DOMESTIC SHEEP; DRUG EFFECTS; ESTRUS CYCLE; FETUS DEVELOPMENT; METABOLISM; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRENATAL EXPOSURE; SEXUAL MATURATION; SHEEP;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; ESTROUS CYCLE; FEMALE; FETAL DEVELOPMENT; FLUTAMIDE; HYPOGLYCEMIC AGENTS; LUTEINIZING HORMONE; METFORMIN; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEXUAL MATURATION; SHEEP; SHEEP, DOMESTIC; TESTOSTERONE; THIAZOLIDINEDIONES;

EID: 84937597108     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1235     Document Type: Article

References (88)

1. Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007;22(6):1506-1512.
2. Boyle J, Teede HJ. Polycystic ovary syndrome - an update. Aust Fam Physician. 2007;41(10):752-756.
3. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):671-683.
4. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 2011;52:401-419.
5. Hampton T. NIH panel: name change, new priorities advised for polycystic ovary syndrome. JAMA. 2013;309(9):863.
6. Burt Solorzano CM, Beller JP, Abshire MY, Collins JS, McCartney CR, Marshall JC. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids. 2012;77(4):332-337.
7. Balen AH. Ovulation induction in the management of anovulatory polycystic ovary syndrome. Mol Cell Endocrinol. 2012;373(1-2):77-82.
8. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand. 2005;84(7):611-616.
9. Homburg R. Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab. 2006;20(2):281-292.
10. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673-683.
11. Amsterdam ESHRE/ASRM-Sponsored Third PCOS Consensus Workshop Group.Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27(1):14-24.
12. Barber TM, Franks S. Genetics of polycystic ovary syndrome. Horm Res. 2013;40:28-39.
13. Barker DJ. The developmental origins of adult disease. J Am Coll Nutr. 2004;23(suppl 6):588S-595S.
14. Padmanabhan V, Veiga-Lopez A. Sheep models of polycystic ovary syndrome phenotype. Mol Cell Endocrinol. 2013;373(1-2):8-20.
15. Davies MJ, Norman RJ. Programming and reproductive functioning. Trends Endocrinol Metab. 2002;13(9):386-392.
16. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update. 2005;11(4):357-374.
17. Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994;79(5):1328-1333.
18. Abbott DH1, Nicol LE, Levine JE, Xu N, Goodarzi MO, Dumesic DA. Nonhuman primate models of polycystic ovary syndrome. Mol Cell Endocrinol. 2013;373:21-28.
19. McNeilly AS, Duncan WC. Rodent models of polycystic ovary syndrome. Mol Cell Endocrinol. 2013;373(1-2):2-7.
20. Padmanabhan V, Veiga-Lopez A. Animal models of polycystic ovary syndrome phenotype. Steroids. 2013;78(8):734-740.
21. Abi Salloum B, Veiga-Lopez A, Abbott DH, Burant CF, Padmanabhan V. Developmental programming: exposure to testosterone excess disrupts steroidal and metabolic environment in pregnant sheep. Endocrinology. Published online ahead of print March 12, 2015. DOI: http://dx.doi.org/10.1210/en.2014-2006.
22. Abbott DH, Bruns CR, Barnett DK, et al. Experimentally induced gestational androgen excess disrupts glucoregulation in rhesus monkey dams and their female offspring. Am J Physiol Endocrinol Metab. 2010;299(5):E741-E751.
23. Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2008;22(2):261-274.
24. Pasquali R, Gambineri A. Insulin sensitizers in polycystic ovary syndrome. Front Horm Res. 2013;40:83-102.
25. Jackson LM, Timmer KM, Foster DL. Sexual differentiation of the external genitalia and the timing of puberty in the presence of an antiandrogen in sheep. Endocrinology. 2008;149(8):4200-4208.
26. Abi Salloum B, Herkimer C, Lee JS, Veiga-Lopez A, Padmanabhan V. Developmental programming: prenatal and postnatal contribution of androgens and insulin in the reprogramming of estradiol positive feedback disruptions in prenatal testosterone-treated sheep. Endocrinology. 2012;153(6):2813-2822.
27. Foster DL, Padmanabhan V, Wood RI, Robinson JE. Sexual differentiation of the neuroendocrine control of gonadotrophin secretion: concepts derived from sheep models. Reprod Suppl. 2002;59:83-99.
28. Padmanabhan V, Veiga-Lopez A. Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming. Semin Reprod Med. 2011;29(3):173-186.
29. Manikkam M, Crespi EJ, Doop DD, et al. Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep. Endocrinology. 2004;145(2):790-798.
30. Veiga-Lopez A, Steckler TL, Abbott DH, et al. Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep. Biol Reprod. 2011;84(1):87-96.
31. Legro RS, Zaino RJ, Demers LM, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol. 2007;196(4):402.e1-e10.
32. Roy KK, Baruah J, Sharma A, et al. A prospective randomized trial comparing the clinical and endocrinological outcome with rosiglitazone versus laparoscopic ovarian drilling in patients with polycystic ovarian disease resistant to ovulation induction with clomiphene citrate. Arch Gynecol Obstet. 2010;281(5):939-944.
33. Veiga-Lopez A, Lee JS, Padmanabhan V. Developmental programming: insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheep. Endocrinology. 2010;151(8):4007-4017.
34. Niswender GD, Reichert LE, Midgley AR, Nalbandov AV. Radioimmunoassay for bovine and ovine luteinizing hormone. Endocrinology. 1969;84(5):1166-1173.
35. Padmanabhan V, Evans NP, Dahl GE, McFadden KL, Mauger DT, Karsch FJ. Evidence for short or ultrashort loop negative feedback of GnRH secretion. Neuroendocrinology. 1995;62(3):248-258.
36. Cohen J. Power primer. Psychol Bull. 1992;112(1):155-159.
37. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc. 2007;82(4)591-605.
38. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25-33.
39. Foster DL, Karsch FJ, Olster DH, Ryan KD, Yellon SM. Determinants of puberty in a seasonal breeder. Recent Prog Horm Res. 1986;42:331-384.
40. Sisk CL, Foster DL. The neural basis of puberty and adolescence. Nat Neurosci. 2004;7(10):1040-1047.
41. Manikkam M, Steckler TL, Welch KB, Inskeep EK, Padmanabhan V. Fetal programming: prenatal testosterone treatment leads to follicular persistence/luteal defects; partial restoration of ovarian function by cyclic progesterone treatment. Endocrinology. 2006;147(4):1997-2007.
42. Wood RI, Foster DL. Sexual differentiation of reproductive neuroendocrine function in sheep. Rev Reprod. 1998;3(2):130-140.
43. Kinder JE, Bergfeld EG, Wehrman ME, Peters KE, Kojima FN. Endocrine basis for puberty in heifers and ewes. J Reprod Fertil Suppl. 1995;49:393-407.
44. Styne DM. Puberty, obesity and ethnicity. Trends Endocrinol Metab. 2004;15(10):472-478.
45. Masek KS, Wood RI, Foster DL. Prenatal dihydrotestosterone differentially masculinizes tonic and surge modes of luteinizing hormone secretion in sheep. Endocrinology. 1999;140(8):3459-3466.
46. Karsch FJ, Bittman EL, Foster DL, Goodman RL, Legan SJ, Robinson JE. Neuroendocrine basis of seasonal reproduction. Recent Prog Horm Res. 1984;40:185-232.
47. Kasa-Vubu JZ, Dahl GE, Evans NP, et al. Progesterone blocks the estradiol-induced gonadotropin discharge in the ewe by inhibiting the surge of gonadotropin-releasing hormone. Endocrinology. 1992;131(1):208-212.
48. Manikkam M, Thompson RC, Herkimer C, et al. Developmental programming: impact of prenatal testosterone excess on pre- and postnatal gonadotropin regulation in sheep. Biol Reprod. 2008;78(4):648-660.
49. Veiga-Lopez A, Ye W, Phillips DJ, Herkimer C, Knight PG, Padmanabhan V. Developmental programming: deficits in reproductive hormone dynamics and ovulatory outcomes in prenatal testosterone-treated sheep. Biol Reprod. 2008;78(4):636-647.
50. Padmanabhan V, Smith P, Veiga-Lopez A. Developmental programming: impact of prenatal testosterone treatment and postnatal obesity on ovarian follicular dynamics. J Dev Origins Health Dis. 2012;3(4):276-286.
51. Veiga-Lopez A, Astapova OI, Aizenberg EF, Lee JS, Padmanabhan V. Developmental programming: contribution of prenatal androgen and estrogen to estradiol feedback systems and periovulatory dynamics in sheep. Biol Reprod. 2009;80(4):718-725.
52. Lund TD, Hinds LR, Handa RJ. The androgen 5α-dihydrotestosterone and its metabolite 5α-androstan-3β,17β-diol inhibit the hypothalamo-pituitary-adrenal response to stress by acting through estrogen receptor β-expressing neurons in the hypothalamus. J Neurosci. 2006;26(5):1448-1456.
53. Pak TR, Chung WC, Hinds LR, Handa RJ. Estrogen receptor-beta mediates dihydrotestosterone-induced stimulation of the arginine vasopressin promoter in neuronal cells. Endocrinology 2007;148(7):3371-3382.
54. Dean A, Sharpe RM. Clinical review: anogenital distance or digit length ratio as measures of fetal androgen exposure: relationship to male reproductive development and its disorders. J Clin Endocrinol Metab. 2013;98(6):2230-2238.
55. Muttukrishna S, Knight PG. Inverse effects of activin and inhibin on the synthesis and secretion of FSH and LH by ovine pituitary cells in vitro. J Mol Endocrinol. 1991;6(2):171-178.
56. Rubianes E, Menchaca A, Carbajal B. Response of the 1-5 day-aged ovine corpus luteum to prostaglandin F2 α. Anim Reprod Sci. 2003;78(1-2):47-55.
57. Wildeus S. Current concepts in synchronization of estrus: sheep and goats. Proc Am Soc Anim Sci. 1999;77:1-14.
58. Padmanabhan V, Veiga-Lopez A. Reproduction Symposium: developmental programming of reproductive and metabolic health. J Anim Sci. 2014;92(8):3199-3210.
59. Steckler T, Manikkam M, Inskeep EK, Padmanabhan V. Developmental programming: follicular persistence in prenatal testosterone-treated sheep is not programmed by androgenic actions of testosterone. Endocrinology. 2007;148(7):3532-3540.
60. Ortega HH, Salvetti NR, Padmanabhan V. Developmental programming: prenatal androgen excess disrupts ovarian steroid receptor balance. Reproduction. 2009;137(5):865-877.
61. Ortega HH, Rey F, Velazquez MML, Padmanabhan V. Developmental programming: effect of prenatal steroid excess on intraovarian components of insulin signaling pathway and related proteins. Biol Reprod. 2010;82(6):1065-1075.
62. Salvetti NR, Ortega HH, Veiga-Lopez A, Padmanabhan V. Developmental programming: impact of prenatal testosterone excess on ovarian cell proliferation and apoptotic factors in sheep. Biol Reprod. 2012;87(1):22, 1-10.
63. Veiga-Lopez A, Ye W, Padmanabhan V. Developmental programming: prenatal testosterone excess disrupts antimullerian hormone expression in preantral and antral follicles. Fertil Steril. 2012;97(3):748-756.
64. Birch RA, Padmanabhan V, Foster DL, Robinson JE. Prenatal programming of reproductive neuroendocrine function: fetal androgen exposure produces progressive disruption of reproductive cycles in sheep. Endocrinology. 2003;144(4):1426-1434.
65. van de Leemput EE, Vos PL, Hyttel P, et al. Effects of brief post-ponement of the preovulatory LH surge on ovulation rates and embryo formation in eCG/prostaglandin-treated heifers. Theriogenology. 2001;55(2):573-592.
66. Butcher RL, Fugo NW. Overripeness and the mammalian ova. II. Delayed ovulation and chromosome anomalies. Fertil Steril. 1967;18(3):297-302.
67. Freeman ME, Butcher RL, Fugo NW. Alteration of oocytes and follicles by delayed ovulation. Biol Reprod. 1970;2(2):209-215.
68. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;5:CD003053.
69. Ibáñez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update. 2006;12(3):243-252.
70. Ibáñez L, Valls C, Ferrer A, Ong K, Dunger DB, De Zegher F. Additive effects of insulin-sensitizing and antiandrogen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemiaand anovulation. J Clin Endocrinol Metab. 2002;87(6):2870-2874.
71. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60(2):241-249.
72. Balfour JA, Plosker GL. Rosiglitazone. Drugs. 1999;57:921-932.
73. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther. 2002;22(10):1151-68; discussion 1149-1150.
74. Glintborg D, Andersen M. Thiazolinedione treatment in PCOS - an update. Gynecol Endocrinol. 2010;26(11):791-803.
75. Bhagavath B, Vitek W, Queenan J, Hoeger K. Metformin and other insulin sensitizers in polycystic ovary syndrome. Semin Reprod Med. 2014;32(4):323-330.
76. Misso ML, Costello MF, Garrubba M, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2013;19(1):2-11.
77. Mousavi SA, Masoumi SZ, Keramat A, Pooralajal J, Shobeiri F. Assessment of questionnaires measuring quality of life in infertile couples: a systematic review. J Reprod Infertil. 2013;14(3):110-119.
78. Luk BH, Loke AY. The impact of infertility on the psychological well-being, marital relationships, sexual relationships, and quality of life of couples: a systematic review. J Sex Marital Ther. 2014;11:1-16.
79. Chachamovich JR, Chachamovich E, Ezer H, Fleck MP, Knauth D, Passos EP. investigating quality of life and health-related quality of life in infertility: a systematic review. J Psychosom Obstet Gynaecol. 2010;31(2):101-110.
80. ESHRE Capri Workshop Group. Health and fertility in World Health Organization group 2 anovulatory women. Hum Reprod Update 2012;18(5):586-599.
81. Apter D. Endocrine and metabolic abnormalities in adolescents with a PCOS-like condition: consequences for adult reproduction. Trends Endocrinol Metab. 1998;9(2):58-61.
82. Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord. 2007;8(2):127-141.
83. Beck-Peccoz P, Padmanabhan V, Baggiani AM, et al. Maturation of hypothalamic-pituitary-gonadal function in normal human fetuses: circulating levels of gonadotropins, their common α-subunit and free testosterone, and discrepancy between immunological and biological activities of circulating follicle-stimulating hormone. J Clin Endocrinol Metab. 1991;73(3):525-532.
84. Apter D. How possible is the prevention of polycystic ovary syndrome development in adolescent patients with early onset of hyperandrogenism. J Endocrinol Invest. 1988;21(9):613-617.
85. Rosenfield RL, Ghai K, Ehrmann DA, Barnes RB. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab. 2000;13(suppl 5):1285-1289.
86. Anderson AD, Solorzano CM, McCartney CR. Childhood obesity and its impact on the development of adolescent PCOS. Semin Reprod Med. 2014;32(3):202-213.
87. Catteau-Jonard S, Cortet-Rudelli C, Richard-Proust C, Dewailly D. Hyperandrogenism in adolescent girls. Endocr Dev. 2012;22:181-193.
88. Golub MS, Collman GW, Foster PM, et al. Public health implications of altered puberty timing. Pediatrics. 2008;121(suppl 3):S218-S230.